Conference Coverage

How to beat apremilast-induced diarrhea

Publish date: March 31, 2016

 

EXPERT ANALYSIS FROM RWCS 2016

References

He reported serving on scientific advisory boards for, and/or as a consultant to, nine pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Minimal disease activity criteria in PsA fall short
Psoriatic Arthritis ICYMI
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasis
Psoriatic Arthritis ICYMI
Don’t overlook topical tazarotene for psoriasis
Psoriatic Arthritis ICYMI
Fresh evidence of methotrexate efficacy in psoriatic arthritis
Psoriatic Arthritis ICYMI
Anti-Remicade antibodies also cross-react with infliximab biosimilar
Psoriatic Arthritis ICYMI
Sparse, poor evidence supports fumarates for psoriasis
Psoriatic Arthritis ICYMI
ACR’s 2016-2020 research agenda built through consensus
Psoriatic Arthritis ICYMI
Home infusion policies called out in ACR position statement
Psoriatic Arthritis ICYMI
Pushback on Part B drug payment proposal already beginning
Psoriatic Arthritis ICYMI
Ixekizumab approved for plaque psoriasis
Psoriatic Arthritis ICYMI